Oncolytics

The Company's technologies are based on discoveries arising from research conducted at the University of Calgary. Dr. Coffey, VP Product Development for the Company was instrumental in these discoveries, and continues to be instrumental in the product development process.

The Company was formed in 1998, to explore the natural oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway.



The product being developed by the Company may represent a novel treatment for certain tumor types and some cellular proliferative disorders. The Company’s product is a virus that is able to replicate specifically in, and hence kill, certain tumor cells both in tissue culture as well as in a number of animal models.



The Company’s product for human use, REOLYSIN®, is the reovirus. This virus has been demonstrated to replicate specifically in tumor cells bearing an activated Ras pathway. Activating mutations of Ras and upstream elements of Ras may play a role in greater than two thirds of all potential tumors.

Contact Details: 210, 1167 Kensington Crescent NW Calgary AB T2N 1X7 Tel: (403) 670-7377 Fax: (403) 283-0858 Email: dougballonc@aol.com WWW: www.oncolyticsbiotech.com/

BioNews Results for Oncolytics:
Treats 200th Cancer Patient in Clinical Studies With REOLYSIN(R)	Therapeutics Daily:  Jul 16 2008 1:12PM Matching: oncolytics
Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)	SmartBrief:  Jul 15 2008 6:20AM Matching: oncolytics
Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)	Financials.com:  Jul 15 2008 1:12AM Matching: oncolytics
Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)	KRON4:  Jul 15 2008 7:34AM Matching: oncolytics
Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)	KOTA Territory News:  Jul 15 2008 1:26AM Matching: oncolytics
Promote your company here: BioNewsCast - Press Release Distribution	→View more Oncolytics news.

Oncolytics Patents:
US Patent No.	Title
7374752	Reovirus for the treatment of cellular proliferative disorders
6808916	Method of extracting virus from cell culture
6703232	Method of producing infectious reovirus
6649157	Viruses for the treatment of cellular proliferative disorders
6596268	Viruses for the treatment of cellular proliferative disorders
→View more Oncolytics patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 251 times since April 2007, the link to the organisation's website has been followed 46 times

Recent Search Terms used to find this page: dougballonc@aol.com | .

Search for more companies in NW Calgary

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Oncolytics